Organogenesis Holdings Stock Alpha and Beta Analysis
| ORGO Stock | USD 3.25 0.07 2.20% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Organogenesis Holdings. It also helps investors analyze the systematic and unsystematic risks associated with investing in Organogenesis Holdings over a specified time horizon. Remember, high Organogenesis Holdings' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Organogenesis Holdings' market risk premium analysis include:
Beta (0.33) | Alpha (0.24) | Risk 3.74 | Sharpe Ratio (0.07) | Expected Return (0.27) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Organogenesis |
Organogenesis Holdings Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Organogenesis Holdings market risk premium is the additional return an investor will receive from holding Organogenesis Holdings long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Organogenesis Holdings. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Organogenesis Holdings' performance over market.| α | -0.24 | β | -0.33 |
Organogenesis Holdings expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Organogenesis Holdings' Buy-and-hold return. Our buy-and-hold chart shows how Organogenesis Holdings performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Organogenesis Holdings Market Price Analysis
Market price analysis indicators help investors to evaluate how Organogenesis Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Organogenesis Holdings shares will generate the highest return on investment. By understating and applying Organogenesis Holdings stock market price indicators, traders can identify Organogenesis Holdings position entry and exit signals to maximize returns.
Organogenesis Holdings Return and Market Media
The median price of Organogenesis Holdings for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 3.55 with a coefficient of variation of 8.77. The daily time series for the period is distributed with a sample standard deviation of 0.31, arithmetic mean of 3.51, and mean deviation of 0.25. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 500000 shares by Gn 2016 Family Trust Uad August 12, 2016 of Organogenesis Holdings at 4.057 subject to Rule 16b-3 | 11/27/2024 |
2 | Organogenesis Holdings Inc. announces an Equity Buyback for 500,000 shares, for 2.03 million. - Marketscreener.com | 12/02/2024 |
3 | Disposition of 1067245 shares by Gillheeney Gary S. of Organogenesis Holdings at 0.99 subject to Rule 16b-3 | 12/05/2024 |
4 | Disposition of 18416 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.65 subject to Rule 16b-3 | 12/06/2024 |
5 | Disposition of 41052 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.52 subject to Rule 16b-3 | 12/09/2024 |
6 | Disposition of 157448 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.64 subject to Rule 16b-3 | 12/11/2024 |
7 | Disposition of 43359 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.55 subject to Rule 16b-3 | 12/12/2024 |
8 | Disposition of 55615 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.36 subject to Rule 16b-3 | 12/13/2024 |
9 | Disposition of 5585 shares by Gillheeney Gary S. of Organogenesis Holdings at 3.49 subject to Rule 16b-3 | 12/16/2024 |
10 | Organogenesis Holdings Inc. CEO Gary S. Gillheeney Sells 55,615 Shares of Stock | 12/17/2024 |
11 | Acquisition by Ades Alan A. of 6401945 shares of Organogenesis Holdings subject to Rule 16b-3 | 01/08/2025 |
12 | Disposition of 3643 shares by Freedman Lori of Organogenesis Holdings at 3.68 subject to Rule 16b-3 | 01/17/2025 |
13 | Analysts Offer Predictions for Organogenesis FY2025 Earnings - MarketBeat | 01/23/2025 |
14 | Disposition of 17972 shares by Erani Albert of Organogenesis Holdings at 4.2775 subject to Rule 16b-3 | 01/28/2025 |
15 | Disposition of 804 shares by David Francisco of Organogenesis Holdings at 3.7 subject to Rule 16b-3 | 02/14/2025 |
16 | Acquisition by Driscoll Michael Joseph of 49575 shares of Organogenesis Holdings subject to Rule 16b-3 | 02/19/2025 |
About Organogenesis Holdings Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Organogenesis or other stocks. Alpha measures the amount that position in Organogenesis Holdings has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 72.41 | 69.1 | 62.19 | 51.53 | PTB Ratio | 1.32 | 1.93 | 2.22 | 2.1 |
Organogenesis Holdings Upcoming Company Events
As portrayed in its financial statements, the presentation of Organogenesis Holdings' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Organogenesis Holdings' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Organogenesis Holdings' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Organogenesis Holdings. Please utilize our Beneish M Score to check the likelihood of Organogenesis Holdings' management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Organogenesis Holdings
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Organogenesis Holdings Backtesting, Organogenesis Holdings Valuation, Organogenesis Holdings Correlation, Organogenesis Holdings Hype Analysis, Organogenesis Holdings Volatility, Organogenesis Holdings History and analyze Organogenesis Holdings Performance. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Organogenesis Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.